Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

The Science of Chronic Itch

Shivani V. Tripathi, MD, & Brian S. Kim, MD, MTR  |  Issue: December 2014  |  December 1, 2014

click for large version
Table 1: Categories of Chronic Pruritus

Neuropathic Itch

In contrast to systemic chronic itch, which is likely mediated by circulating factors or pruritogens, neuropathic itch derives from pathology along the afferent nervous system.41 The nervous system can be activated either centrally or peripherally. Tumors or degenerative diseases of the CNS (e.g., multiple sclerosis) can lead to centrally mediated mechanisms of pruritus.42

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

More commonly, neuropathic itch is triggered within the PNS. For example, viral damage to peripheral neurons is thought to mediate postherpetic itch in a manner similar to postherpetic neuralgia.43,44

Another example of peripherally mediated pruritus includes notalgia paresthetica, which presents as chronic, localized itch most often on the central back. Although the exact etiology remains unknown for notalgia paresthetica, it has been theorized that sensory nerve entrapment, involving the posterior rami of the T2 to T6 nerve root, occurs due to degenerative changes in the vertebrae.45 In a similar fashion, brachioradial pruritus manifests as chronic, intermittent pruritus along the arms and is thought to be caused by nerve impingement along the cervical spine.46

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

For the treatment of neuropathic itch, a variety of neuromodulators are employed empirically. For example, topical capsaicin has been shown to improve symptoms in notalgia parasthetica.47 The mechanism of action of capsaicin is activation of the sensory nerve receptor TRPV1, which leads to depletion of substance P and neuronal desensitization.48 For postherpetic itch and brachioradial pruritus, gabapentin has demonstrated efficacy as well.49 Its mechanism of action is believed to be via binding of the α2δ1 subunit of voltage-dependent calcium channels in dorsal horn postsynaptic cells.50

Other treatments attempted in neuropathic itch include oxcarbazepine, botulinum toxin or, in the case of nerve entrapment, physical therapy and/or surgery.

Psychogenic Itch

Psychogenic pruritus is a diagnosis of exclusion that presents in association with an underlying psychiatric disorder, such as obsessive-compulsive disorder (OCD), anxiety disorder or substance abuse.41 Associated conditions include neurotic excoriations or excoriation disorder, which is now recognized in the DSM-V manual.51 These diseases are strongly influenced by variations in life events and stress. Typical findings include excoriations, erosions, ulcers and scarring in areas of the body that can be easily manipulated by the patient, such as the extensor surfaces and face.52 Delusions of parasitosis, a relatively uncommon psychiatric condition, presents with the patient having a fixed belief that he or she has been infested with arthropods or parasites.53 The patient suffers from these delusions and consciously produces self-inflicted wounds as a result.

Page: 1 2 3 4 5 6 7 | Single Page
Share: 

Filed under:ConditionsEducation & TrainingMyositisProfessional TopicsResearch Rheum Tagged with:chronic pruritusitchKimmyositispathophysiologypatient careResearchrheumatology

Related Articles

    Psoriasis May Itch as Intensely as Atopic Dermatitis

    June 13, 2017

    NEW YORK (Reuters Health)—Itch intensity in moderate to severe plaque psoriasis can be substantial, and may be on a par with the notoriously itchy skin condition atopic dermatitis, new research suggests. “Both conventional wisdom and some of our classic dermatologic textbooks have stated that psoriasis is not particularly itchy,” corresponding author Dr. Alexa B. Kimball…

    How to Manage Pain in Patients with Renal Insufficiency or End-Stage Renal Disease on Dialysis

    October 1, 2013

    Narcotic and non-narcotic pain regimens can be used

    Lost and found

    The History of ACE Inhibitors in Scleroderma Renal Crisis

    February 16, 2021

    Scleroderma renal crisis is a true medical emergency in rheumatology, one that requires prompt diagnosis and treatment. Here, we review the historic introduction of the angiotensin-converting enzyme inhibitors in this context, and highlight management and key questions moving forward. Background Awareness of renal disease in scleroderma dates back many years. The revered physician William Osler…

    MicroOne / shutterstock.com

    Rheumatology Drugs at a Glance, Part 2: Psoriasis

    May 17, 2019

    Over the past few years, bio­similars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug option; others have few or only off-label options. This series, “Rheumatology Drugs at a Glance,” provides streamlined information on the administration of biologic, biosimilar and other medications used to…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences